Evidence map›Paper›PMID 21185810›Full record

SynthesisChemico-biological interactions2011

The effect of disease associated point mutations on 5β-reductase (AKR1D1) enzyme function.

Rebekka Mindnich, Jason E Drury, Trevor M Penning

Open access · greenAbstract readMeta-Analysis
In one paragraph

Synthesis in Chemico-biological interactions, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The aldo-keto reductases (AKRs): Overview.Chemico-biological interactions · 2015
    Review
  6. Review
  7. Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice.Drug metabolism and disposition: the biological fate of chemicals · 2013
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Rebekka MindnichUniversity of Pennsylvania, School of Medicine, Department of Pharmacology, Philadelphia, PA 19104-6084, USA.
Jason E Drury
Trevor M Penning
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Structure/Function of Steroid Transforming AKR'sR01DK047015 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI PENNING, TREVOR M · 1994 to 2011
$3.2M
Enzymology and Molecular Biology of Carbonyl Metabolism XVR13AA019612 · NIAAA · PURDUE UNIVERSITY · PI WEINER, HENRY · 2010 to 2010
$31k
Symposium on Aldo-Keto Reductases &Toxicant MetabolismR13CA097985 · NCI · UNIVERSITY OF PENNSYLVANIA · PI PENNING, TREVOR M. · 2002 to 2002
$10k
NCI NIH HHS R13 CA097985NIAAA NIH HHS R13 AA019612NIAAA NIH HHS R13-AA019612NIDDK NIH HHS 5-R01-DK047015-13NIDDK NIH HHS R01 DK047015NIEHS NIH HHS P30 ES013508NIEHS NIH HHS P30-ES013508
6 · The paper itself

Abstract

The stereospecific 5β-reduction of Δ(4)-3-ketosterols is very difficult to achieve chemically and introduces a 90° bend between ring A and B of the planar steroid. In mammals, the reaction is catalyzed by steroid 5β-reductase, a member of the aldo-keto reductase (AKR) family. The human enzyme, AKR1D1, plays an essential role in bile-acid biosynthesis since the 5β-configuration is required for the emulsifying properties of bile. Deficient 5β-reductase activity can lead to cholestasis and neo-natal liver failure and is often lethal if it remains untreated. In five patients with 5β-reductase deficiency, sequencing revealed individual, non-synonymous point mutations in the AKR1D1 gene: L106F, P133R, G223E, P198L and R261C. However, mapping these mutations to the AKR1D1 crystal structure failed to reveal any obvious involvement in substrate or cofactor binding or catalytic mechanism, and it remained unclear whether these mutations could be causal for the observed disease. We analyzed the positions of the reported mutations and found that they reside in highly conserved portions of AKR1D1 and hypothesized that they would likely lead to changes in protein folding, and hence enzyme activity. Attempts to purify the mutant enzymes for further characterization by over-expression in Escherichia coli yielded sufficient amounts of only one mutant (P133R). This enzyme exhibited reduced K(m) and k(cat) values with the bile acid intermediate Δ(4)-cholesten-7α-ol-3-one as substrate reminiscent of uncompetitive inhibition. In addition, P133R displayed no change in cofactor affinity but was more thermolabile as judged by CD-spectroscopy. When all AKR1D1 mutants were expressed in HEK 293 cells, protein expression levels and enzyme activity were dramatically reduced. Furthermore, cycloheximide treatment revealed decreased stability of several of the mutants compared to wild type. Our data show, that all five mutations identified in patients with functional bile acid deficiency strongly affected AKR1D1 enzyme functionality and therefore may be causal for this disease.

Indexed as

Point MutationAnimalsBile Acids and SaltsConserved SequenceDiseaseHEK293 CellsHumansOxidoreductases3-oxo-5 beta-steroid delta 4-dehydrogenaseBile Acids and SaltsOxidoreductases

Identifiers

PMID21185810
PMCPMC3101292
OpenAlexW2093795670

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.